|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Predictors of kidney tubular dysfunction induced by adefovir treatment for chronic hepatitis B显示文摘AIM:To investigate the predictors of proximal kidney tubular dysfunction(PKTD)induced by adefovir dipivoxil(ADV)treatment for chronic hepatitis B.METHODS:Seventy-nine patients(age at the evaluation of PKTD:56.9±10.7 years)with chronic hepatitis B undergoing long-term oral antiviral nucleos(t)ide analogue treatment were consecutively recruited.PKTD was defined by the presence of at least two of the following five abnormalities:phosphate diabetes,nondiabetic glucosuria,metabolic acidosis,β2-microglobulinuria,or renal hypouricemia.The single-nucleotide polymorphisms(SNPs)in the SLC22A6 gene encoding human organic anion transporter 1(h OAT1)and ABCC2 encoding multidrug resistance protein 2(MRP2)were analyzed using the Taq Man Allelic Discrimination Demonstration Kit.RESULTS:Nine(30.0%)of the 30 ADV-treated patients were diagnosed with PKTD,while no patients without ADV developed PKTD(P<0.001).Three patients with ADV were diagnosed with symptomatic osteomalacia.Among the patients who took ADV,those with PKTD were of higher age at initiation,had significantly longer treatment duration,and had a significantly lower body mass index than those without PKTD.The incidence of PKTD dramatically increased after 96 mo from the start of ADV administration.In contrast,the SNPs were not correlated with PKTD.Logistic regression analysis extracted older age at initiation(OR=5.0,95%CI:1.1-23.4;P=0.040)and longer treatment duration(OR=3.2,95%CI:1.2-8.6;P=0.020)as significant factors associated with PKTD.CONCLUSION:Our results suggest that the tubular function of the kidney of older patients undergoing longterm ADV treatment should be carefully evaluated. | Motohiro Shimizu Norihiro Furusyo Hiroaki Ikezaki Eiichi Ogawa Takeo Hayashi Takeshi Ihara Yuji Harada Kazuhiro Toyoda Masayuki Murata Jun Hayashi | 2015 | World Journal of Gastroenterology2015，21，7： | 18 |
| 2 | Interferon alpha plus ribavirin combination treatment of Japanese chronic hepatitis C patients with HCV genotype 2:A project of the Kyushu University Liver Disease Study Group显示文摘瞄准:决定一座干扰素高山的功效哈并且为感染遗传型 2 的丙肝病毒(HCV ) 的日本病人的 ribavirin 联合治疗,多中心研究回顾地被分析。方法:总共,有 HCV 遗传型 2 的 173 个病人每天一个星期和 ribavirin 的 600-800 mg 为 24 wk 三次皮下地收到 interferon-alpha。结果:总的来说持续的 virological 反应(SVR ) ,在浆液的定义同样无法发现的 HCV RNA,在治疗的结束以后的 24 wk,在 84.4% 显著地高,(146/173 ) 由 intention-to-treat 分析。在 SVR 的有效差量有或没有 ribavirin (46.9% 对 92.9%) 的中止在病人之间被发现,但是没有差别有或没有 ribavirin 的剂量减小在那些之间被发现。在 SVR 的有效差量也与 16 或更与不到 16 wk 和病人在病人之间被发现 ribavirin 治疗(34.8% 对 92.0%) 的星期。结论:24-wk 干扰素和 ribavirin 治疗为有 HCV 遗传型 2 的日本病人是高度有效的。SVR 的重要预言者是 ribavirin 治疗的继续多达 16 个星期。 | Norihiro Furusyo Masaki Katoh Yuichi Tanabe Eiji Kajiwara Toshihiro Maruyama Junya Shimono Hironori Sakai Makoto Nakamuta Hideyuki Nomura Akihide Masumoto Shinji Shimoda Kazuhiro Takahashi Koichi Azuma Jun Hayashi Kyushu University Liver Disease Study Group | 2006 | World Journal of Gastroenterology2006，12，5： | 8 |
| 3 | Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis C: A prospective, multicenter study显示文摘 | Eiichi Ogawa Norihiro Furusyo Eiji Kajiwara Kazuhiro Takahashi Hideyuki Nomura Toshihiro Maruyama Yuichi Tanabe Takeaki Satoh Makoto Nakamuta Kazuhiro Kotoh Koichi Azuma Kazufumi Dohmen Shinji Shimoda Jun Hayashi | 2012 | Journal of Hepatology2012，，： | 3 |
| 4 | Long-term effects of lamivudine treatment in Japanese chronic hepatitis B patients显示文摘AIM:To analyze the association between the emergence of tyrosine-methionine-asparatate-asparatate(YMDD) mutants(reverse transcription;rtM204I/V) and deterioration of liver function during long-term lamivudine treatment of Japanese patients with chronic hepatitis B virus(HBV) infection.METHODS:The data of 61 consecutive Japanese patients with chronic hepatitis B who underwent continuous lamivudine treatment for more than 24 mo and had a virological response were analyzed.Analysis of YMDD mutants was done by real-time polymerase chain reaction with LightCycler probe hybridization assay for up to 90 mo(mean,50.8 mo;range,24-90 mo).RESULTS:A mixed mutant-type(YMDD + tyrosine-isoleucine-asparatate-asparatate:YIDD or tyrosine-valineasparatate-asparatate:YVDD) or a mutant-type(YIDD or YVDD) were found in 57.4% of 61 patients at 1 year,78.7% of 61 patients at 2 years,79.6% of 49 patients at 3 years,70.5% of 34 patients at 4 years,68.4% of 19 patients at 5 years,57.1% of 14 patients at 6 years,and 33.3% of 6 patients at 7 years.Of the 61 patients,56(92%) had mixed mutant-or a mutant-type.Only 5(8%) had no mutants at each observation point.Virological breakthrough was found in 26(46.4%) of 56 patients with YMDD mutants,20 of whom had a hepatitis flare-up:the remaining 30(53.6%) had neither a virological breakthrough nor a flare-up.All 20 patients who developed a hepatitis flare-up had a biochemical and virological response after adefovir was added to the lamivudine treatment.CONCLUSION:Our results suggest that it is possible to continue lamivudine treatment,even after the emergence of YMDD mutants,up to the time that the patients develop a hepatitis flare-up. | Masayuki Murata Norihiro Furusyo Mami Unno Eiichi Ogawa Kazuhiro Toyoda Hiroaki Taniai Hachiro Ohnishi Jun Hayashi | 2011 | World Journal of Gastroenterology2011，17，24： | 3 |
| 5 | The longitudinal quantitative assessment by transient elastography of chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin显示文摘 | Eiichi Ogawa Norihiro Furusyo Kazuhiro Toyoda Hiroaki Takeoka Shinji Maeda Jun Hayashi | 2009 | Antiviral Research2009，，2： | 2 |
| 6 | Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C显示文摘 | Norihiro Furusyo Eiichi Ogawa Makoto Nakamuta Eiji Kajiwara Hideyuki Nomura Kazufumi Dohmen Kazuhiro Takahashi Takeaki Satoh Koichi Azuma Akira Kawano Yuichi Tanabe Kazuhiro Kotoh Shinji Shimoda Jun Hayashi | 2013 | Journal of Hepatology2013，，2： | 2 |
| 7 | Pre-treatment role of inosine triphosphate pyrophosphatase polymorphism for predicting anemia in Egyptian hepatitis C virus patients显示文摘AIM: To investigate and clarify, for the first time, the role of inosine triphosphate pyrophosphatase (ITPA ) polymorphism in Egyptian chronic hepatitis C virus (HCV) patients.METHODS:The human genomic DNA of all patients was extracted from peripheral blood cells in order to determine the single nucleotide polymorphism (SNP) of ITPA (rs1127354). SNP genotyping was performed by real time polymerase chain reaction (PCR, ABI TaqMan allelic discrimination kit) for 102 treatment-naive Egyptian patients with chronic HCV. All patients had no evidence of cardiovascular or renal diseases. They received a combination treatment of pegylated interferon α (PEG-IFNα) as a weekly subcutaneous dose plus an oral weight-adjusted dose of ribavirin (RBV). The majority received PEG-IFNα2a (70.6%) while 29.4% received PEG-IFNα2b. The planned duration of treatment was 24-48 wk according to the viral kinetics throughout the course of treatment. Pre-treatment liver biopsy was done for each patient for evaluation of fibrosis stage and liver disease activity. The basal viral load level was detected quantitatively by real time PCR while viral load throughout the treatment course was performed qualitatively by COBAS TaqMan assay. RESULTS: Ninety-three patients (91.2%) had ITPA SNP CC genotype and 9 (8.8%) had non-CC genotype (CA and AA). The percentage of hemoglobin (Hb) decline was higher for CC patients than for non-CC patients, particularly at weeks 4 and 8 (P=0.047 and 0.034, respectively). During the first 12 wk of treatment, CC patients had significantly more Hb decline > 3 g/dL than non-CC patients: 64.5% vs 22.2% at weeks 8 and 12, respectively, (P=0.024 and 0.038). Reduction of the amount of the planned RBV dose was significantly higher for CC patients than non-CC patients during the first 12 wk (18% ± 12.1% vs 8.5% ± 10.2%, P=0.021). The percentage of CC patients with RBV dose reduction was significantly greater than that of non-CC patients (77.4% vs 44.4%, P=0.044). Multivariate analysis identified only the percentage of RBV dose as a predictor for Hb decline. Platelet decline was significantly higher in non-CC patients than CC patients at weeks 12, 24 and 48 (P=0.018, 0.009 and 0.026, respectively). CONCLUSION: Rs1127354 ITPA polymorphism plays a decisive role in protecting against treatment-induced anemia and the need for RBV dose reduction in Egyptian HCV patients. | Walaa H Ahmed Norihiro Furusyo Saad Zaky Abeer Sharaf Eldin Hany Aboalam Eiichi Ogawa Masayuki Murata Jun Hayashi | 2013 | World Journal of Gastroenterology2013，19，9： | 2 |
| 8 | The elimination of hepatitis B virus infection:changing seroepidemiology of hepatitis A and B virus infection in Okinawa Japan Over A26-year period显示文摘 | Norihiro Furusyo Jun Hayashi Yasunori Sawayama | 1998 | Am J Med Hyp1998，59，5： | 1 |
| 9 | Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy显示文摘 | Eiichi Ogawa Norihiro Furusyo Makoto Nakamuta Eiji Kajiwara Hideyuki Nomura Kazufumi Dohmen Kazuhiro Takahashi Takeaki Satoh Koichi Azuma Akira Kawano Yuichi Tanabe Kazuhiro Kotoh Shinji Shimoda Jun Hayashi | 2013 | Journal of Hepatology2013，，： | 1 |
| 10 | Effect on carotid atherosclerosis of probucol plus levofloxacin for Chlamydia pneumoniae infection显示文摘 | Yasunori Sawayama Masafumi Tatsukawa Kensuke Kikuchi Shinji Maeda Hachiro Ohnishi Norihiro Furusyo Jun Hayashi | 2007 | Journal of Infection and Chemotherapy2007，，2： | 1 |
| 11 | Insulin resistance undermines the advantages of IL28B polymorphism in the pegylated interferon alpha-2b and ribavirin treatment of chronic hepatitis C patients with genotype 1显示文摘 | Eiichi Ogawa Norihiro Furusyo Masayuki Murata Hiroaki Ikezaki Takeshi Ihara Takeo Hayashi Kazuhiro Toyoda Hiroaki Taniai Kyoko Okada Mosaburo Kainuma Jun Hayashi | 2012 | Journal of Hepatology2012，，3： | 1 |
| 12 | Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C<!-- Doctopic: VH -->显示文摘 | Norihiro Furusyo Eiichi Ogawa Makoto Nakamuta Eiji Kajiwara Hideyuki Nomura Kazufumi Dohmen Kazuhiro Takahashi Takeaki Satoh Koichi Azuma Akira Kawano Yuichi Tanabe Kazuhiro Kotoh Shinji Shimoda Jun Hayashi | 2013 | Journal of Hepatology2013，，2： | 1 |
| 13 | Relationship between body surface area and ALT normalization after long-term lamivudine treatment显示文摘AIM: To further evaluate the relationship between BSA and the effects of lamivudine in a greater number of cases and over a longer period of observation than in our previous evaluation.METHODS: We evaluated 249 patients with chronic hepatitis B. The effects of treatment for one year (n = 249),two years (n = 147), and three years (n = 72) were evaluated from the levels of serum ALT and HBV-DNA,as biological and virological effects (undetectable levels by PCR), respectively. Moreover, several variables that could influence the response to treatment, including ALT,albumin, bilirubin, platelet counts, BSA, HBV-DNA, and HBeAg were analyzed.RESULTS: For 1-year treatment, multivariate analysis revealed that BSA (P=0.0002) was the only factor for the biological effect, and that ALT (P = 0.0017), HBVDNA (P = 0.0004), and HBeAg (P = 0.0021) were independent factors for the virological effect. For 2-year treatment, multivariate analysis again showed that BSA(P = 0.0147) was the only factor for the biological effect,and that ALT (P = 0.0192) and HBeAg (P = 0.0428) were independent factors for the virological effect. For 3-year treatment, multivariate analysis, however, could not reveal BSA (P = 0.0730) as a factor for the normalization of ALT levels.CONCLUSION: BSA is a significant predictor for the normalizing the effect of lamivudine therapy on ALT for an initial 2-year period, suggesting that lamivudine dosage should be based on the individual BSA. | Makoto Nakamuta Shusuke Morizono Yuichi Tanabe Eiji Kajiwara Junya Shimono Akihide Masumoto Toshihiro Maruyama Norihiro Furusyo Hideyuki Nomura Hironori Sakai Kazuhiro Takahashi Koichi Azuma Shinji Shimoda Kazuhiro Kotoh Munechika Enjoji Jun Hayashi Kyushu University liver Disease Study Group | 2005 | World Journal of Gastroenterology2005，11，44： | 1 |
| 14 | G Virus in the General Population and in Patients on Hemodialysis显示文摘 | Jun Hayashi Norihiro Furusyo Yasunori Sawayama Yasuhiro Kishihara Yasunobu Kawakami Iwao Ariyama Yoshitaka Etoh Seizaburo Kashiwagi | 1998 | Digestive Diseases and Sciences1998，，9： | 1 |
| 15 | Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy<!-- Doctopic: VH -->显示文摘 | Eiichi Ogawa Norihiro Furusyo Makoto Nakamuta Eiji Kajiwara Hideyuki Nomura Kazufumi Dohmen Kazuhiro Takahashi Takeaki Satoh Koichi Azuma Akira Kawano Yuichi Tanabe Kazuhiro Kotoh Shinji Shimoda Jun Hayashi | 2013 | Journal of Hepatology2013，，： | 1 |
| 16 | Pegylated interferon α-2b plus ribavirin for older patients with chronic hepatitis C显示文摘AIM:To analyze the efficacy and safety of a combination therapy of pegylated interferon(PEG-IFN) α-2b plus ribavirin(RBV) in older Japanese patients(65 years or older) infected with hepatitis C virus(HCV).METHODS:This multicenter study included 938 patients with HCV genotype 1 who received 1.5 μg/kg per week PEG-IFN α-2b plus RBV 600-1000 mg/d for 48 wk and 313 HCV genotype 2 patients who received this treatment for 24 wk.RESULTS:At 24 wk after the end of combination therapy,the overall sustained virological response(SVR) for genotypes 1 and 2 were 40.7% and 79.6%,respectively.The SVR rate decreased signif icantly with age in each genotype,and was markedly reduced in genotype 1(P<0.001).Moreover,the SVR was significantly higher in patients with genotype 1 who were less than 65 years(47.3% of 685) than in those 65 years or older(22.9% of 253)(P<0.001) and was higher in patients with genotype 2 who were less than 65 years(82.9% of 252) than in those 65 years or older(65.6% of 61)(P=0.004).When patients received a dosage at least 80% or more of the target dosage of PEG-IFN α-2b and 60% or more of the target dosage of RBV,the SVR rate significantly increased to 66.5% in patients less than 65 years and to 45.2% in those 65 years or older(P<0.001).Adverse effects resulted in treatment discontinuation more often in patients with genotype 1(14.4%) than in patients with genotype 2(7.3%),especially by patients 65 years or older(24.1%).CONCLUSION:PEG-IFN α-2b plus RBV treatment was effective in chronic hepatitis C patients 65 years or older who completed treatment with at least the minimum acceptable treatment dosage. | Mosaburo Kainuma Norihiro Furusyo Eiji Kajiwara Kazuhiro Takahashi Hideyuki Nomura Yuichi Tanabe Takeaki Satoh Toshihiro Maruyama Makoto Nakamuta Kazuhiro Kotoh Koichi Azuma Junya Shimono Shinji Shimoda Jun Hayashi | 2010 | World Journal of Gastroenterology2010，16，35： | 1 |
| 17 | Long-term lamivudine treatment for chronic,hepatitis B in Japanese patients:A project of Kyushu University Liver Disease Study显示文摘瞄准:与长期的肝炎 B 决定很多日本病人的长期的 lamivudine 治疗的功效。方法:在这回顾,多中心试用,有长期的肝炎 B 的 318 个日本病人每天为多达 36 收到了 lamivudine 的 100 mg (中部 21 ) 瞬间。Virological 反应是到浆液 HBV DNA 水平的衰落不到 3.7 木头 copies/mL。当浆液 HBV DNA 的再现在 treatment.RESULTS 期间铺平最小到超过 10 褶层, Virological 突破被定义:Lamivudine 在 6 瞬间在 318 个病人中的 86.8% 个生产了 virological 反应,在在 12 瞬间的 252 个病人中的 80.2% 个,在在 24 瞬间的 133 个病人中的 69.2% 个,并且在在 36 瞬间的 28 个病人中的 53.6% 个。向前逐步的逻辑回归分析证明 HBV DNA 铺平不到 6.8 木头 copies/mL ( P<0.0001 ), HBeAg 否定性( P<0.0001 ), 100 x 10 的一个血小板计数( 9 )在基线的 /L 或更多( P=0.0162 ),并且超过 3.2 木头 copies/mL 的 HBV DNA 水平的衰落在治疗( P=0.0003 )的开始以后在 3 瞬间作为与基线相比铺平显著地与 virological 反应被联系。在有 virological 回答的病人之中, virological 突破在在 1 瞬间 virologically 反应了的 19 个病人中的5.3%个被看见,在在 3 瞬间的 203 个病人中的20.7%个,在在 6 瞬间的 51 个病人中的27.5%个,在在 9 瞬间的 12 个病人中的33.3%个,并且在在 >=5 瞬间的 3 个病人的100%。virological 突破与推迟的 virological response.CONCLUSION 在病人更经常显著地被发现:Lamivudine 治疗能在大多数测试日本病人压制浆液 HBV DNA。没有 HBeAg,长期的功效可能在基线在病人被看见,当肝硬化不在时,并且在有在 HBV 的衰落的病人, DNA 此后不久铺平治疗的开始。 | Norihiro Furusyo Hiroaki Takeoka Kazuhiro Toyoda Masayuki Murata Yuichi Tanabe Eiji Kajiwara Junya Shimono Akihide Masumoto Toshihiro Maruyama Hideyuki Nomura Makoto Nakamuta Kazuhiro Takahashi Shinji Shimoda Koichi Azuma Hironori Sakai Jun Hayashi | 2006 | World Journal of Gastroenterology2006，12，4： | 1 |
| 18 | Serum Soluble Interleukin-2 Receptor Levels Before and During Interferon Treatment in Patients with Chronic Hepatitis B Virus Infection显示文摘 | Yasunori Sawayama Jun Hayashi Yasunobu Kawakami Norihiro Furusyo Iwao Ariyama Yasuhiro Kishihara Kumiko Ueno Seizaburo Kashiwagi | 1999 | Digestive Diseases and Sciences1999，，1： | 1 |
| 19 | Plasma glycated albumin level and atherosclerosis: Results from the Kyushu and Okinawa Population Study (KOPS)显示文摘 | Norihiro Furusyo Tsunehisa Koga Masumi Ai Seiko Otokozawa Takuji Kohzuma Hiroaki Ikezaki Ernst J. Schaefer Jun Hayashi | 2012 | International Journal of Cardiology2012，，： | 1 |
| 20 | Influence of low-density lipoprotein cholesterol on virological response to telaprevir-based triple therapy for chronic HCV genotype 1b infection显示文摘 | Eiichi Ogawa Norihiro Furusyo Eiji Kajiwara Hideyuki Nomura Kazufumi Dohmen Kazuhiro Takahashi Makoto Nakamuta Takeaki Satoh Koichi Azuma Akira Kawano Yuichi Tanabe Kazuhiro Kotoh Shinji Shimoda Jun Hayashi | 2014 | Antiviral Research2014，，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员